Catalyst Wire Dossier Catalyst Wire Dossier

Baricitinib (Olumiant)

baricitinib · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Baricitinib (Olumiant), covering 2025-05-13 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis [Phase 3]

See pricing